{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:16:04Z","timestamp":1792451764013,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009992","name":"Seattle Children's Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018762","name":"Seattle Children's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M and Harry B Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtm.2025.101561","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:47:00Z","timestamp":1755154020000},"page":"101561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["HLA-A2 CAR\/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory function"],"prefix":"10.1016","volume":"33","author":[{"given":"Subhash K.","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaiz","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle P.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchi","family":"Honaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker","family":"Knebusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-1776","authenticated-orcid":false,"given":"David J.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101561_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-pathol-020117-043720","article-title":"New Insights into Graft-Versus-Host Disease and Graft Rejection","volume":"13","author":"Perkey","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.omtm.2025.101561_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa6853","article-title":"Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation","volume":"7","author":"McDonald-Hyman","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101561_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jmcb\/mjr047","article-title":"CD4(+)Foxp3(+) regulatory T cell therapy in transplantation","volume":"4","author":"Tang","year":"2012","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.omtm.2025.101561_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41434-022-00358-x","article-title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","volume":"30","author":"Proics","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101561_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021752","article-title":"Treg Therapy for the Induction of Immune Tolerance in Transplantation-Not Lost in Translation?","volume":"24","author":"Pilat","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101561_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101561_bib8","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtm.2025.101561_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101561_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtm.2025.101561_bib11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101561_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101561_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2025.101561_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtm.2025.101561_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.it.2023.04.005","article-title":"Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond","volume":"44","author":"Bittner","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omtm.2025.101561_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad007","article-title":"Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective","volume":"3","author":"Sakaguchi","year":"2023","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.omtm.2025.101561_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo2628","article-title":"Selective decrease of donor-reactive T(regs) after liver transplantation limits T(reg) therapy for promoting allograft tolerance in humans","volume":"14","author":"Tang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtm.2025.101561_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101561_bib22","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/ajt.17063","article-title":"Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival","volume":"22","author":"Wagner","year":"2022","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtm.2025.101561_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167215","article-title":"Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection","volume":"8","author":"Rosado-Sanchez","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101561_bib24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtm.2025.101561_bib25","article-title":"Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtm.2025.101561_bib26","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2025.101561_bib27","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.omtm.2025.101561_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MOT.0b013e32833bfadc","article-title":"Adoptive regulatory T cell therapy: challenges in clinical transplantation","volume":"15","author":"Safinia","year":"2010","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.omtm.2025.101561_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib30","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.ymthe.2023.04.021","article-title":"A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells","volume":"31","author":"Cook","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101561_bib31","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2023.07.016","article-title":"Dual-locus, dual-HDR editing permits efficient generation of antigen-specific regulatory T cells with robust suppressive activity","volume":"31","author":"Hunt","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101561_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171844","article-title":"GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes","volume":"9","author":"Uenishi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101561_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0198-8859(99)00155-X","article-title":"Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A\u221702011 and identification of HLA-A\u22170231","volume":"61","author":"Ellis","year":"2000","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.omtm.2025.101561_bib56","unstructured":"Levings, M., Orban, P., Dawson, N., Lamarche, C., and Bergqvist, J.P. (2021). Anti-Hla-A2 Antibodies And Methods Of Using The Same, EP3684821A4, European Patent Office, June 16, 2021."},{"key":"10.1016\/j.omtm.2025.101561_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib36","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T cell function","volume":"5","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101561_bib37","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2016.12.008","article-title":"Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells","volume":"4","author":"Hale","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101561_bib39","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtm.2025.101561_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864748","article-title":"Cytolytic CD4(+) and CD8(+) Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease","volume":"13","author":"Bolivar-Wagers","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101561_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib42","doi-asserted-by":"crossref","first-page":"13395","DOI":"10.1074\/jbc.M700498200","article-title":"The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain","volume":"282","author":"Edwards","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101561_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136185","article-title":"CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD","volume":"5","author":"Imura","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101561_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101561_bib45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/ajt.15700","article-title":"Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation","volume":"20","author":"Sanchez-Fueyo","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtm.2025.101561_bib46","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/ajt.16395","article-title":"Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients","volume":"21","author":"Harden","year":"2021","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtm.2025.101561_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","article-title":"CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2","volume":"17","author":"Malek","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.omtm.2025.101561_bib48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization","volume":"201","author":"Setoguchi","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtm.2025.101561_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-065X.2011.01004.x","article-title":"T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells","volume":"241","author":"Cheng","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omtm.2025.101561_bib50","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","article-title":"In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2025.101561_bib51","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1038\/s41467-021-26844-1","article-title":"Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction","volume":"12","author":"Lamarthee","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101561_bib52","article-title":"High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells","author":"Cochrane","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtm.2025.101561_bib53","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtm.2025.101561_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166135","article-title":"Opportunities for Treg cell therapy for the treatment of human disease","volume":"14","author":"Bluestone","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101561_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002076","article-title":"Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells","volume":"3","author":"Sagoo","year":"2011","journal-title":"Sci. Transl. Med."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:19:43Z","timestamp":1762615183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2329050125001561"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101561","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HLA-A2 CAR\/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory function","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101561"}}